- Home
- JYD vs THAR Comparison
JYD vs THAR Comparison
Compare JYD & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- THAR
- Stock Information
- Founded
- JYD 2001
- THAR 2017
- Country
- JYD China
- THAR United States
- Employees
- JYD N/A
- THAR N/A
- Industry
- JYD Oil Refining/Marketing
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- THAR Health Care
- Exchange
- JYD Nasdaq
- THAR Nasdaq
- Market Cap
- JYD 18.9M
- THAR 16.8M
- IPO Year
- JYD 2023
- THAR 2022
- Fundamental
- Price
- JYD $0.13
- THAR $3.18
- Analyst Decision
- JYD
- THAR Strong Buy
- Analyst Count
- JYD 0
- THAR 1
- Target Price
- JYD N/A
- THAR $17.00
- AVG Volume (30 Days)
- JYD 4.9M
- THAR 644.6K
- Earning Date
- JYD 10-24-2025
- THAR 11-06-2025
- Dividend Yield
- JYD N/A
- THAR N/A
- EPS Growth
- JYD N/A
- THAR N/A
- EPS
- JYD N/A
- THAR N/A
- Revenue
- JYD $77,444,271.00
- THAR N/A
- Revenue This Year
- JYD N/A
- THAR N/A
- Revenue Next Year
- JYD N/A
- THAR N/A
- P/E Ratio
- JYD N/A
- THAR N/A
- Revenue Growth
- JYD 13.54
- THAR N/A
- 52 Week Low
- JYD $0.09
- THAR $0.95
- 52 Week High
- JYD $8.00
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- JYD 39.38
- THAR 49.85
- Support Level
- JYD $0.12
- THAR $2.88
- Resistance Level
- JYD $0.16
- THAR $3.17
- Average True Range (ATR)
- JYD 0.02
- THAR 0.31
- MACD
- JYD -0.00
- THAR -0.00
- Stochastic Oscillator
- JYD 16.98
- THAR 40.22
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.